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Abstract 
Involvement of the K: opioid receptor in the regulation of epileptic activity was studied in WAG/Rij rats, a genetic model of absence 
epilepsy. I.e. v. administration of the K: agonists U50,488H { trans-3,4-dichloro-N-methyi-N-[2-(1-pyrrolidynyl)-cyclohexyl]-
benzeneacetamide}, U69,593 (Sa, 1a,Sp)-(-)-N-methyl-(1-pyrrolidinyl)-1-oxaspiro( 4,5)dec-8-yl)benzeneacetamide) or PD 117,302 
((±)-trans-N-methyi-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzo[b ]thiophene-4-acetamide), 50 and 150 f1.g/5f1.l each, dose-dependently de-
creased the number and mean duration of spike wave discharges (SWD). Peripheral administration of U50,488H (10 and 30 mglkg s.c.) 
also attenuated the seizure activity in this model. The specific K: opioid receptor antagonist nor-binaltorphimine (Nor-BNI, 10 flg/Sfll 
i.c.v., 18 h before EEG registration) moderately increased the number of SWD, which suggests that endogenous opioids acting through 
K: receptors may tonically inhibit the seizure activity in these rats. In addition, the enhancement of an absence-like seizure activity 
induced by the specific ll opioid receptor agonist o-Aia2-N-methyi-Phe4-Giy5-ol-enkephalin (DAMGO, 0.7/.lg/5/.ll i.c.v.) was also 
attenuated in rats pretreated with U50,488H, U69,593 or PD117,302. These data indicate that activation of the K: opioid receptor exerts 
an inhibitory effect on absence-like seizure activity in WAG/Rij rats. 
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Opioids exert both pro- and anticonvulsant effects de-
pending on the seizure model, animal species, route of 
drug administration and, most importantly, on the type of 
the opioid receptor involved [2,14,15]. In this respect a 
new generation of K opioid receptor agonists deserves 
attention, since these compounds show consistent anti-
convulsive properties in several models of generalized 
tonic-clonic and limbic seizures [ 12,17 ,20]. In contrast, a 
possible role of K opioid receptors in the regulation of 
non-convulsive generalized seizures (absence seizures) 
remains unclear. In the test for screening potential anti-
absence drugs for fluorothyl-induced seizures, the spe-
cific K opioid agonist U50,488H was not effective [17]; 
on the other hand, the endogenous K receptor agonist 
dynorphin suppresses pentetrazole-induced seizures [13]. 
Corroboration of the effectiveness of K opioid receptor 
agonists in absence seizures could be attained by experi-
ments on animals with spontaneous absence seizures. It 
has been proposed that W AG/Rij rats, which spontane-
ously show trains of 7-10Hz spike-wave discharges 
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(SWD) in the cortical BEG [1,9,19], are a suitable genetic 
model of human absence epilepsy, which has been vali-
dated by pharmacological studies [9]. We showed previ-
ously that stimulation of the It opioid receptor in these 
rats strongly potentiated the number of SWD whereas the 
o opioid receptor appeared not to be involved [6]. On the 
other hand, agonists of K opioid receptor showed anticon-
vulsant effects in various convulsive seizure models 
[12,13,17,20], however, their role in non-convulsive epi-
lepsy has not been studied as yet. Therefore, in the pres-
ent study we investigated the involvement of K opioid 
receptor in the regulation of absence-like seizures in 
W AG/Rij rats. 
Male, 6-month-old, epileptic W AG/Rij rats, weighing 
250--325 g, kept in an animal house on a reversed 12112 
light-dark cycle (lights on at 2000 h), were used as ex-
perimental subjects. During the experiment, the rats were 
housed singly, one to a cage, and the investigations were 
carried out in the dark period (red light), between 0900 
and 1600 h. They had free access to standard laboratory 
food and water. The rats were implanted with cortical 
electrodes (Plastics One, MS 333/2-A) and an i.c.v. guide 
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cannula under pentobarbital anaesthesia (Narcovet, 
60 mglkg). The electrodes were placed on the surface of 
the cortex, one in the frontal region (coordinates with the 
skull surface flat and bregma zero-zero: A 2.0, L 3.5) and 
the other in the parietal region (A -6.0, L 4.0). The 
ground electrode was placed in the cerebellum. A poly-
ethylene cannula (inner diameter 0.4 mm, outer diameter 
0.8 mm) was placed contralaterally to the electrodes in 
the left lateral ventricle (A 0.7, L -1.3) at a depth of 
3.5 mm from the skull surface. Upon the termination of 
the experiment, the rats were killed by an overdose of 
pentobarbital, and the location of the cannula was veri-
fied. After the surgery the animals were allowed to re-
cover for 1 week; afterwards, they were put into a trans-
parent recording cage (25 X 25 X 35 em). Finally, the 
rats were connected to EEG leads and habituated for 24 h. 
The K. receptor agonists U50,488H (Upjohn Company), 
U69,593 (Upjohn Company) and PD117,302 (Parke and 
Davis) were dissolved in Ringer's solution and injected 
i.c.v. in a volume of 5 ,ul twice (cumulative dose), first 
with a low dose (50 ,ug) and 1 h later with a higher dose 
(150 ,ug). In other experiments U50,488H was dissolved 
in physiological saline and injected s.c. only once. Con-
trol rats received Ringer's solution i.c.v. or physiological 
saline s.c., respectively. Nor-BNI (Research Biochemicals 
Internationals, Natick, MA, USA) was injected in a dose 
of 10,ug, 18 h before EEG registration. In a separate ex-
periment, the rats were injected with U50,488H, U69,593, 
PD117 ,302 (150 ,ug/5 ,ul i.c.v.) or Ringer (5 ,ul i.c.v.) 1 h 
before injection of the specific .u receptor agonist 
DAMGO (Sigma) in a dose of 0.7 ,ug/5 ,ul i.c.v. EEG was 
recorded for 1 h after i.c.v. or 2 h after s.c. drug admini-
stration. The rats were observed from an adjacent room 
and the time of the exploratory (exploration, sniffing, 
rearing), automatic (eating, drinking, grooming) and pas-
sive (sleeping, immobility) behaviour was scored using a 
behavioural recording system (The Observer, Noldus, 
1991). 
The majority of the rats were used only once; in some 
cases they were used for a second time after no less than 
6 days. The EEG with frequencies between 1 and 70 Hz 
was monitored, digitalized and stored for off-line analysis 
using an ACODAS system as described previously [6]. 
The number of trains of SWDs and their mean duration 
per subject per hour were determined and these data were 
statistically analysed by ANOVA followed by Duncan's 
test. 
U50,488H (50 and 150 ,ug i.e. v .) decreased dose-
dependently the number of SWD, and tended to decrease 
their mean duration. U69,593 (50 and 150 ,ug i.c.v.) also 
dose-dependently decreased the number of SWD; when 
used in a higher dose, it significantly shortened the mean 
duration of SWD. PD117,302 in a dose of 50,ug i.c.v. 
showed no effect; however, given in a dose of 150 ,ug, it 
significantly decreased both the number and mean dura-
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Fig. 1. The effect of IC receptor agonists: U50,488H (USO), U69,593 
(U69) and PD117,302 (PD) injected i.c.v. first at a low dose 
(50 ,ug/5 ,ul) and 1 h later at a higher dose (150 ,ug/5 ,ul) on the number 
of trains of spike wave discharges (SWD) and their mean duration. The 
results are the mean± SEM of 6-12 rats per group. *P < 0.05 versus 
control. 
i.c.v. in a dose of 50,ug changed the behaviour, however, 
a dose of 150 ,ug evoked a decrease in the automatic be-
haviour and slightly enhanced the passive behaviour. 
U50,488H injected in doses of 10 and 30 mglkg s.c. 
decreased the number of SWD in a dose- and time-
dependent manner, the effect being more pronounced at 
the second hour of EEG registration (Table 1). No signifi-
cant changes in mean duration of SWD were noted after 
the U50,488H s.c. administration (data not shown). Peri-
pheral injections of 30 and 50 mg/kg of U50,488H re-
duced the time of explorative and automatic behaviour 
and enhanced passive behaviour in a dose-dependent 
manner. At the highest dose used, the rats were almost 
completely immobile. 
Nor-BNI injected i.c.v. in a dose of 10,ug 18 h before 
EEG registration increased the number of SWD (control 
18.6 ± 2.9, Nor-BNI 28.3 ± 3.0, P < 0.05 ANOV A). No 
changes in the duration of SWD (control 6.2 ± 0.3, Nor-
BNI 5.2 ± 0.3), as well as in behaviour, were observed 
after Nor-BNI administration. 
In agreement with a previous study [6], DAMGO 
(0.7 ,ug/5 ,ul i.c.v.) markedly increased the number of 
SWD. This effect was significantly attenuated in rats pre-
treated with U50,488H and PD117,302 (Fig. 2). In rats 
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Table I 
The effects of subcutaneous injection of U50,488H (U50) in different 
doses on the number of trains of spike wave discharges (SWD)/subject 
per hour in WAG/Rij rats 
Dose (mglkg) 1st hour after U50 2nd hour after U50 
0.9%NaCl 33.7 ± 3.0 30.3 ± 2.3 
U50 (10) 27.3 ± 4.5 24.9 ± 6.4 
U50 (30) 20.0 ± 3.1 9.8± 1.1* 
U50(50) 16.8 ± 5.1 * 10.6 ± 2.6* 
Results are the mean± SEM for 6-12 rats per group. *P < 0.05. 
pretreated with U69,593 the effect of DAMGO on the 
number of SWD tended to decrease, but did not reach 
statistical significance. DAMGO alone or after pretreat-
ment with U50,488H and U69,593 had no effect on mean 
duration of SWD (data not shown). The mean duration of 
SWD after DAMGO and PD117,302 was significantly 
shorter compared to controls (6.5 ± 0.6 and 3.8 ± 0.5, 
respectively, P < 0.05). 
All the K agonists used in our study decreased the 
number and mean duration of SWD. This anti-absence 
effect was also observed after central and, as was shown 
for U50,488H, peripheral administration. Inhibition of 
both the number and mean duration of SWD indicates 
that stimulation of tht: K receptor prevents generation of 
SWD, and inhibits the ongoing seizure activity in 
W AG/Rij rats. The effect appears, despite the fact that the 
substances studied evoke a visible calming effect which 
facilitates development of SWD. The latter are found 
mainly during slow-wave sleep and passive wakefulness 
[19]. Therefore it is unlikely that the suppression of ab-
sence seizures should stem from the effect of the K ago-
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Fig. 2. The effect of DAM GO injected at a dose 0.7 flg/5 fll i.c.v. 1 h 
after 150flg/5fll i.c.v. of U50,488H (U50), U69,593 (U69) and 
PD117,302 (PD) on the number of trains of spike wave discharges 
(SWD) and their mean duration. The results are the mean ± SEM of 6-9 
rats per group. *P < 0.05 versus control, #p < 0.05 versus DAMGO 
alone. 
Agonists of K opioid receptors are efficient anticonvul-
sants in spontaneous and electrically or chemically in-
duced generalized convulsive seizures, which are animal 
models of grand mal epilepsy [17,20]. It should be noted 
that some drugs used for the treatment of grand mal sei-
zures, such as phenytoin, have no effect or even aggravate 
absence seizures; therefore it seems that K agonists de-
velop unique pharmacological characteristics, being ef-
fective in both types of epilepsy. The neurochemical 
mechanism of protective effects of K agonists in rats with 
spontaneous absence epilepsy remains unknown. One of 
possible explanation is an inhibitory influence of K ago-
nists on excitatory amino acids [20], which are known to 
play an important role in regulation of absence seizures in 
W AG/Rij rats [8]. Stimulation of " receptors has an in-
hibitory effect on voltage-dependent calcium channels, 
but the significance of this mechanism in the regulation of 
absence seizures will require further studies. 
In our experiment, Nor-BNI, a specific " opioid an-
tagonist [11], caused an increase in the number of SWD. 
As was shown in our previous study, naloxone also pro-
moted the occurrence of SWD [6]. The latter effect was 
likely to be mediated by antagonism towards K receptors, 
since specific antagonists of 11- and o receptors (8-funal-
trexamine and naltrindole) had no effect on SWD [6). 
These facts suggest that endogenous opioids, which act 
through the K receptors (e.g. prodynorphin-derived pep-
tides), tonically control the initiation of absence seizures 
in W AG/Rij rats. Indeed, a biochemical study showed 
that, in comparison with non-epileptic controls, epileptic 
W AG/Rij rats showed changes in both the proenkephalin 
and the prodynorphin peptides level as well as respective 
mRNAs in discrete brain areas [5,7]. 
In our model, K receptor agonists not only act in a way 
opposite to 11- receptor agonists [3,6], but can also attenu-
ate the DAM GO-induced increase in the number of SWD. 
This finding is in line with reports that K opioid receptor 
agonists can antagonize some effects of 11- agonists, i.e . 
dynorphin has been found to antagonize the effects of 
morphine in a variety of tests in vivo [ 4, 18], similarly, 
U50,488H antagonizes the effect of ethorphine on the 
fluorothyl-induced seizures threshold [10] and the bladder 
effects of 11- agonists at spinal sites in rats [15]. Our data 
provide further evidence that activation of 11- and K opioid 
receptors may, under certain conditions, influence the 
excitability of the nervous system in opposite ways. 
In conclusion, our data indicate that K opioid receptor 
agonists may be regarded as potential drugs against ab-
sence seizures, moreover, they suggest that K receptors 
are tonically involved in the suppression of SWD genera-
tion in W AG/Rij rats. 
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